

New Products - Extavia

Extavia (**interferon beta-1b (rbe)**) is indicated for the treatment of patients with a single clinical event suggestive of multiple sclerosis (MS) and at least two clinically silent magnetic resonance imaging (MRI) lesions characteristic of MS, if alternative diagnoses have been excluded. It is also indicated for the treatment of ambulatory patients with relapsing-remitting MS characterised by at least two attacks of neurologic dysfunction over a two year period followed by complete or incomplete recovery. Extavia is also indicated for the reduction of frequency and severity of clinical relapses, and for the slowing of progression of disease in patients with secondary progressive MS. Extavia is contraindicated in patients with a history of hypersensitivity to natural or recombinant interferon beta. Extavia is available as a powder for injection.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.